Skip to main content

Business description

Manufacturer and Supplier of a broad range of emerging pathogens including Zika virus and human proteins, antibodies, disease state plasma for pharmaceutical vaccine development, research laboratories and the in-vitro diagnostics industry.

Products and services

• In vitro diagnostic raw materials
• Human and animal proteins
• Human and animal antibodies
• Disease state Plasmas
• Licensed IP in the field of electrochemical diagnostics

Value proposition

Aalto Bio Reagents is a leading global manufacturer and developer of emerging recombinant pathogens and antibodies with a particular focus on the rapidly growing tropical disease sector including Zika Virus. We closely monitor disease outbreaks and emerging disease trends, enabling us to respond quickly to develop and supply our customers and partners with the relevant raw materials for their own product development requirements. Our highly experienced technical team act as an extension of our clients R & D function, offering technical advice and customised solutions to suit their individual needs. As many of our clients work to tight production deadlines, our logistics department liaise directly with them to schedule custom shipments to suit their manufacturing schedules, as well as offer advice on shipping requirements and documentation.

Our customers include both the largest in-vitro diagnostic companies, pharmaceutical & biotech companies, vaccine developers as well as large research organisations and CRO’s worldwide.

As proof of our value, we were the first Irish-based developer of biological raw materials to achieve ISO 13485 CE IVD standards and in addition hold a Category 3 dept. of Agriculture certification for animal by-products . We were also awarded both Innovator of the Year and Exporter of the Year at the 2017 SFA Annual Awards, and we have recently been short-listed for an Irish Exporters Association Award.

Standards and certificates

  • ISO:13485, Category 3 Approved facility D.O.A under EC no. 1069 of 2009 and Regulation EU No.142 of 2011

Key partners